Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161506 · ClinicalTrials.gov registry record · Phase 2
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
A Phase 2 study of Stress Urinary Incontinence and Urinary Urge Incontinence, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06161506: Recruiting Phase 2 study of Stress Urinary Incontinence and Urinary Urge Incontinence, sponsored by National Cancer Institute (NCI).
NCT06161506 is a Phase 2 study of Stress Urinary Incontinence and Urinary Urge Incontinence that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, below the 162-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161506, a Phase 2 study of Stress Urinary Incontinence and Urinary Urge Incontinence, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Objective: To see if the Elidah device can reduce urinary incontinence after prostate treatment. Eligibility: Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer. Design: Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests. The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis. Participants will be given an Elidah device and taught how to use it at home. They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks. Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads. Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used. Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment. Participants will complete 15-minute questionnaires.
Primary Outcome
Percent decrease in 24-hour pad weight after treatment with the Elidah device.
Conditions Studied
Interventions
- DEVICE Elidah Device
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
What NCT06161506 shows while recruiting
NCT06161506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 162-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Elidah Device is the first listed.
NCT06161506 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06161506 about?
NCT06161506 is a clinical study titled "Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer". Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Objective: To see if the Elidah device can reduce urinary incontinence after p...
What is the current status of trial NCT06161506?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-02-15. Estimated completion is 2028-03-01.
What conditions does trial NCT06161506 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence, Urinary Urge Incontinence, Prostatic Hyperplasia.
What interventions are being tested in trial NCT06161506?
The interventions under investigation include: Elidah Device (DEVICE).
Who is sponsoring clinical trial NCT06161506?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161506 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161506's enrollment target sits among peer trials
41 32nd of 35 higher than 4 of 35 other Stress Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
COMPLETED · Phase 2
-
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
COMPLETED · Phase 2
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI